PharmaShots Interview: Medidata’s Ben Schlatka Shares Insights on Agreement with Labcorp to Advance the Use of Medical-Grade Sensors

In an interview with PharmaShots, Ben Schlatka, Vice President, Digital Biomarker Solutions at Medidata share his views on the Agreement with Labcorp to expand decentralized clinical trial capabilities and digital biomarker discovery using Medidata Sensor Cloud Shots: The companies collaborated to advance the use of medical-grade sensors & accelerate biomarker discovery in clinical research including an at-home version of 6MWT…

BySenior EditorDecember 6, 2021

VIEWPOINTS

PharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease

In an interview with PharmaShots, Dr. Murat Kalayoglu, MD, Ph.D., President, and Chief Executive Officer at Cartesian Therapeutics shared his insights on the P-I/IIa study of Descartes-08 for the treatment of the chronic autoimmune disorder generalized myasthenia gravis (gMG) Shots: Descartes-08 is an autologous T-cell product that is engineered with RNA to encode for CAR The company focuses to use…

BySenior EditorDecember 1, 2021

VIEWPOINTS

PharmaShots Interview: Vivacare’s Mark Becker Shares Insight on the Digital Patient Education Service for Allergic Conditions

In an interview with PharmaShots, Mark Becker, MD, founder, President, and CEO at Vivacare shared his views on the new collaboration with Asthma and Allergy Network to provide a Digital patient education service for allergic conditions Shots: Vivacare and the AAN collaborated to develop a digital patient education service for members regarding allergies, asthma, eczema, and…

BySenior EditorNovember 30, 2021

VIEWPOINTS

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on the Data of Guardant360 Liquid Biopsy Test for the Treatment of Advanced Non-Small Cell Lung Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the data from the VALUE study of Guardant360 liquid biopsy test for NSCLC Shots: The VALUE study evaluates the clinical outcomes & utility of liquid biopsy vs tissue biopsy testing in patients with NSCLC across six Canadian centers In an initial diagnosis, patients treated…

BySenior EditorNovember 29, 2021

VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shared his views on the data from 13 P-II & III studies of Stelara (ustekinumab) for the treatment of IBD and other approved indications Shots: The company has reported the data from 13 P-II & III studies, including 6 studies…

BySenior EditorNovember 24, 2021

VIEWPOINTS

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen for the Treatment of Leber Congenital Amaurosis (LCA10)

In an interview with PharmaShots, Daniel A. de Boer, Founder, and CEO at ProQR shared his views on the P-II/III Illuminate study of sepofarsen for the treatment of leber congenital amaurosis (LCA10) Shots: The ongoing P-II/III Illuminate study evaluates sepofarsen in 36 adults and children aged ≥8yrs. with LCA10. The results are expected in late Q1 or early Q2’22 In the P-I/II clinical…

BySenior EditorNovember 23, 2021

VIEWPOINTS

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLC Shots: The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitor The results showed…

BySenior EditorNovember 22, 2021

VIEWPOINTS

PharmaShots Interview: NervGen’s Paul Brennan Shares Insights on NVG-291 and its Interim Data for the Treatment of Neurodegenerative Diseases

In an interview with PharmaShots, Paul Brennan, President, CEO & Director at NervGen shared his views on the interim data of NVG-291 for the treatment of Neurodegenerative Diseases Shots: The P-I clinical trials evaluate NVG-291 vs PBO in healthy volunteers with neurodegenerative diseases such as AD and MS. The interim results were presented at ANA 146th annual meeting The interim…

BySenior EditorNovember 17, 2021

VIEWPOINTS

PharmaShots Interview: Paracrine’s Christopher J. Calhoun Shares Insight on the First Autologous, Device-Based Cell Therapy Platform

In an interview with PharmaShots, Christopher J. Calhoun, President & CEO at Paracrine shared his views on the transforming diabetes treatment with the first autologous, device-based cell therapy platform Shots: The company has developed the first autologous, device-based cell therapy platform which is ideally positioned to address conditions with underlying integers Paracrine is a one-time, completely natural procedure that…

BySenior EditorNovember 16, 2021

VIEWPOINTS

PharmaShots Interview: Thermo Fisher Scientific Garret Hampton Shares Insight on the Multiyear Agreement with AstraZeneca for NGS-based CDx

In an interview with PharmaShots, Garret Hampton, President of Clinical Next-Generation Sequencing and Oncology at Thermo Fisher Scientific share his views on multiyear agreement with AstraZeneca to co-develop NGS-based CDx for targeted therapies Shots: The collaboration will expand AstraZenecas portfolio of targeted therapies for cancer & other diseases. Thermo Fisher currently offers the NGS CDx solution which is approved…

BySenior EditorNovember 9, 2021

PharmaShots Interview: Medidata’s Ben Schlatka Shares Insights on Agreement with Labcorp to Advance the Use of Medical-Grade Sensors

PharmaShots Interview: Cartesian Therapeutics’s Dr. Murat Kalayoglu Shares Insight on RNA Cell Therapy for an Autoimmune Disease

PharmaShots Interview: Vivacare’s Mark Becker Shares Insight on the Digital Patient Education Service for Allergic Conditions

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on the Data of Guardant360 Liquid Biopsy Test for the Treatment of Advanced Non-Small Cell Lung Cancer

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data of Stelara (ustekinumab) for IBD and other Approved Indications and Presented 13 Abstracts at UEGW

PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen for the Treatment of Leber Congenital Amaurosis (LCA10)

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

PharmaShots Interview: NervGen’s Paul Brennan Shares Insights on NVG-291 and its Interim Data for the Treatment of Neurodegenerative Diseases

PharmaShots Interview: Paracrine’s Christopher J. Calhoun Shares Insight on the First Autologous, Device-Based Cell Therapy Platform

PharmaShots Interview: Thermo Fisher Scientific Garret Hampton Shares Insight on the Multiyear Agreement with AstraZeneca for NGS-based CDx

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter